AZD-2811 is under clinical development by AstraZeneca and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect AZD-2811’s likelihood of approval (LoA) and phase transition for Small-Cell Lung Cancer took place on 13 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AZD-2811 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
AZD-2811 overview
AZD-2811 is under development for the treatment of small-cell lung cancer. It is administered through intravenous route in the form of suspension. The drug candidate is an accurin containing AZD1152-hQPA, which acts by targeting aurora kinase B. It is based on Medicinal Nanoengineering platform. It was also under development for diffuse large B-cell lymphoma, and naive myelodysplastic syndrome.
It was under development for the treatment of hematological malignancies including treatment-naive and relapsed or refractory acute myeloid leukemia and solid tumors.
AstraZeneca overview
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
Quick View AZD-2811 LOA Data
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Developers |
|
Highest Development Stage |
|